• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无局灶节段性肾小球硬化的人类 TRPC6 通道失活突变。

An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis.

机构信息

BIH Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

Fraunhofer-Institute for Biomedical Engineering (IBMT), Fraunhofer Project Center for Stem Cell Process Engineering, Würzburg, Germany.

出版信息

Cell Mol Life Sci. 2023 Aug 24;80(9):265. doi: 10.1007/s00018-023-04901-w.

DOI:10.1007/s00018-023-04901-w
PMID:37615749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10449997/
Abstract

Transient receptor potential cation channel-6 (TRPC6) gene mutations cause familial focal segmental glomerulosclerosis (FSGS), which is inherited as an autosomal dominant disease. In patients with TRPC6-related FSGS, all mutations map to the N- or C-terminal TRPC6 protein domains. Thus far, the majority of TRPC6 mutations are missense resulting in increased or decreased calcium influx; however, the fundamental molecular mechanisms causing cell injury and kidney pathology are unclear. We report a novel heterozygous TRPC6 mutation (V691Kfs*) in a large kindred with no signs of FSGS despite a largely truncated TRPC6 protein. We studied the molecular effects of V691Kfs* TRPC6 mutant using the tridimensional cryo-EM structure of the tetrameric TRPC6 protein. The results indicated that V691 is localized at the pore-forming transmembrane region affecting the ion conduction pathway, and predicted that V691Kfs* causes closure of the ion-conducting pathway leading to channel inactivation. We assessed the impact of V691Kfs* and two previously reported TRPC6 disease mutants (P112Q and G757D) on calcium influx in cells. Our data show that the V691Kfs* fully inactivated the TRCP6 channel-specific calcium influx consistent with a complete loss-of-function phenotype. Furthermore, the V691Kfs* truncation exerted a dominant negative effect on the full-length TRPC6 proteins. In conclusion, the V691Kfs* non-functional truncated TRPC6 is not sufficient to cause FSGS. Our data corroborate recently characterized TRPC6 loss-of-function and gain-of-function mutants suggesting that one defective TRPC6 gene copy is not sufficient to cause FSGS. We underscore the importance of increased rather than reduced calcium influx through TRPC6 for podocyte cell death.

摘要

瞬时受体电位阳离子通道 6 (TRPC6) 基因突变导致家族性局灶节段性肾小球硬化症 (FSGS),该病呈常染色体显性遗传。在 TRPC6 相关 FSGS 患者中,所有突变均位于 N 端或 C 端 TRPC6 蛋白结构域。迄今为止,大多数 TRPC6 突变是错义突变,导致钙内流增加或减少;然而,导致细胞损伤和肾脏病变的基本分子机制尚不清楚。我们报道了一个大型家族中存在一种新的杂合性 TRPC6 突变 (V691Kfs*),尽管 TRPC6 蛋白大部分缺失,但该家族无 FSGS 迹象。我们使用四聚体 TRPC6 蛋白的三维冷冻电镜结构研究了 V691Kfs* TRPC6 突变体的分子效应。结果表明,V691 位于形成孔的跨膜区域,影响离子传导途径,预测 V691Kfs* 导致离子传导途径关闭,从而导致通道失活。我们评估了 V691Kfs* 和之前报道的两种 TRPC6 疾病突变体 (P112Q 和 G757D) 对细胞内钙内流的影响。我们的数据表明,V691Kfs* 完全失活了 TRCP6 通道特有的钙内流,与完全丧失功能表型一致。此外,V691Kfs* 截短对全长 TRPC6 蛋白表现出显性负效应。总之,无功能的 V691Kfs* 截断 TRPC6 不足以导致 FSGS。我们的数据与最近表征的 TRPC6 功能丧失和获得功能突变体一致,表明一个有缺陷的 TRPC6 基因拷贝不足以导致 FSGS。我们强调了通过 TRPC6 增加钙内流而不是减少钙内流对 podocyte 细胞死亡的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/2001d7ab3367/18_2023_4901_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/70b82a032e58/18_2023_4901_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/8a62de207ddb/18_2023_4901_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/2e6e77953e72/18_2023_4901_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/3861d40bb6a0/18_2023_4901_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/e0815a48adc7/18_2023_4901_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/089c61665a94/18_2023_4901_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/8d97c20097ac/18_2023_4901_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/2001d7ab3367/18_2023_4901_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/70b82a032e58/18_2023_4901_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/8a62de207ddb/18_2023_4901_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/2e6e77953e72/18_2023_4901_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/3861d40bb6a0/18_2023_4901_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/e0815a48adc7/18_2023_4901_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/089c61665a94/18_2023_4901_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/8d97c20097ac/18_2023_4901_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00fc/11072566/2001d7ab3367/18_2023_4901_Fig8_HTML.jpg

相似文献

1
An inactivating human TRPC6 channel mutation without focal segmental glomerulosclerosis.无局灶节段性肾小球硬化的人类 TRPC6 通道失活突变。
Cell Mol Life Sci. 2023 Aug 24;80(9):265. doi: 10.1007/s00018-023-04901-w.
2
TRPC6 G757D Loss-of-Function Mutation Associates with FSGS.TRPC6基因G757D功能丧失性突变与局灶节段性肾小球硬化相关。
J Am Soc Nephrol. 2016 Sep;27(9):2771-83. doi: 10.1681/ASN.2015030318. Epub 2016 Feb 18.
3
Novel gain-of-function mutation of TRPC6 Q134P contributes to late onset focal segmental glomerulosclerosis in a Chinese pedigree.TRPC6 Q134P 新型获得性功能突变导致中国一个家系中迟发性局灶节段性肾小球硬化。
Nephrology (Carlton). 2021 Dec;26(12):1018-1025. doi: 10.1111/nep.13963.
4
The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury.钙依赖性蛋白酶钙蛋白酶-1 将 TRPC6 活性与足细胞损伤联系起来。
J Am Soc Nephrol. 2018 Aug;29(8):2099-2109. doi: 10.1681/ASN.2016111248. Epub 2018 Jun 28.
5
Contribution of Coiled-Coil Assembly to Ca/Calmodulin-Dependent Inactivation of TRPC6 Channel and its Impacts on FSGS-Associated Phenotypes.卷曲螺旋组装对钙/钙调蛋白依赖性 TRPC6 通道失活的贡献及其对 FSGS 相关表型的影响。
J Am Soc Nephrol. 2019 Sep;30(9):1587-1603. doi: 10.1681/ASN.2018070756. Epub 2019 Jul 2.
6
A novel TRPC6 mutation that causes childhood FSGS.一个导致儿童局灶节段性肾小球硬化症的新型 TRPC6 突变。
PLoS One. 2009 Nov 10;4(11):e7771. doi: 10.1371/journal.pone.0007771.
7
Identification and functional analysis of a novel TRPC6 mutation associated with late onset familial focal segmental glomerulosclerosis in Chinese patients.中国患者中与迟发性家族性局灶节段性肾小球硬化相关的新型TRPC6突变的鉴定与功能分析
Mutat Res. 2009 May 12;664(1-2):84-90. doi: 10.1016/j.mrfmmm.2008.11.021. Epub 2008 Dec 13.
8
TRPC6 and FSGS: the latest TRP channelopathy.瞬时受体电位通道蛋白6(TRPC6)与局灶节段性肾小球硬化症(FSGS):最新的瞬时受体电位通道病
Biochim Biophys Acta. 2007 Aug;1772(8):859-68. doi: 10.1016/j.bbadis.2007.03.005. Epub 2007 Mar 20.
9
New TRPC6 gain-of-function mutation in a non-consanguineous Dutch family with late-onset focal segmental glomerulosclerosis.一个非近亲结婚的荷兰家族中发现新的 TRPC6 功能获得性突变,与晚发性局灶节段性肾小球硬化症有关。
Nephrol Dial Transplant. 2013 Jul;28(7):1830-8. doi: 10.1093/ndt/gfs572. Epub 2013 Jan 4.
10
Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2).瞬时受体电位 C6(TRPC6)中的功能获得性突变激活细胞外信号调节激酶 1/2(ERK1/2)。
J Biol Chem. 2013 Jun 21;288(25):18407-20. doi: 10.1074/jbc.M113.463059. Epub 2013 May 3.

引用本文的文献

1
Single-Cell RNA Sequencing Delineates Renal Anti-Fibrotic Mechanisms Mediated by TRPC6 Inhibition.单细胞RNA测序揭示TRPC6抑制介导的肾脏抗纤维化机制
Adv Sci (Weinh). 2025 Sep;12(33):e01175. doi: 10.1002/advs.202501175. Epub 2025 Jun 17.
2
Focus on podocytes: diabetic kidney disease and renal fibrosis - a global bibliometric analysis (2000-2024).聚焦足细胞:糖尿病肾病与肾纤维化——一项全球文献计量分析(2000 - 2024年)
Front Pharmacol. 2024 Nov 15;15:1454586. doi: 10.3389/fphar.2024.1454586. eCollection 2024.
3
Natural History and Clinicopathological Associations of TRPC6-Associated Podocytopathy.

本文引用的文献

1
Gain-of-function, focal segmental glomerulosclerosis Trpc6 mutation minimally affects susceptibility to renal injury in several mouse models.功能获得性、局灶节段性肾小球硬化症 Trpc6 突变在几种小鼠模型中对肾脏损伤的易感性影响很小。
PLoS One. 2022 Aug 1;17(8):e0272313. doi: 10.1371/journal.pone.0272313. eCollection 2022.
2
Limiting Transactivator Amounts Contribute to Transgene Mosaicism in Tet-On All-in-One Systems.限制转录激活剂的用量有助于 Tet-On 全合一系统中转基因的嵌合体。
ACS Synth Biol. 2022 Aug 19;11(8):2623-2635. doi: 10.1021/acssynbio.2c00036. Epub 2022 Jul 11.
3
In Vivo Inhibition of TRPC6 by SH045 Attenuates Renal Fibrosis in a New Zealand Obese (NZO) Mouse Model of Metabolic Syndrome.
与TRPC6相关的足细胞病的自然史及临床病理关联
J Am Soc Nephrol. 2025 Feb 1;36(2):274-289. doi: 10.1681/ASN.0000000501. Epub 2024 Oct 1.
4
Podocyte-targeted therapies - progress and future directions.足细胞靶向治疗 - 进展与未来方向。
Nat Rev Nephrol. 2024 Oct;20(10):643-658. doi: 10.1038/s41581-024-00843-z. Epub 2024 May 9.
SH045 通过抑制 TRPC6 减轻代谢综合征新西兰肥胖(NZO)小鼠模型的肾脏纤维化。
Int J Mol Sci. 2022 Jun 20;23(12):6870. doi: 10.3390/ijms23126870.
4
Structural mechanism of human TRPC3 and TRPC6 channel regulation by their intracellular calcium-binding sites.人类 TRPC3 和 TRPC6 通道受其细胞内钙结合位点调节的结构机制。
Neuron. 2022 Mar 16;110(6):1023-1035.e5. doi: 10.1016/j.neuron.2021.12.023. Epub 2022 Jan 19.
5
Dysregulated Dynein-Mediated Trafficking of Nephrin Causes INF2-related Podocytopathy.免疫球蛋白超家族域包含 2 型肌动蛋白结合蛋白相关足细胞病的 Nephrin 失调的动力蛋白介导的运输。
J Am Soc Nephrol. 2021 Feb;32(2):307-322. doi: 10.1681/ASN.2020081109. Epub 2020 Dec 22.
6
TRPC6 channel and its implications in breast cancer: an overview.TRPC6 通道及其在乳腺癌中的意义:概述。
Biochim Biophys Acta Mol Cell Res. 2020 Dec;1867(12):118828. doi: 10.1016/j.bbamcr.2020.118828. Epub 2020 Aug 18.
7
TRPC6 Binds to and Activates Calpain, Independent of Its Channel Activity, and Regulates Podocyte Cytoskeleton, Cell Adhesion, and Motility.TRPC6 与钙蛋白酶结合并激活钙蛋白酶,而不依赖其通道活性,并调节足细胞细胞骨架、细胞黏附和运动。
J Am Soc Nephrol. 2019 Oct;30(10):1910-1924. doi: 10.1681/ASN.2018070729. Epub 2019 Aug 15.
8
Role of TRPC6 in Progression of Diabetic Kidney Disease.TRPC6 在糖尿病肾病进展中的作用。
Curr Hypertens Rep. 2019 May 21;21(7):48. doi: 10.1007/s11906-019-0960-9.
9
Renal Fibrosis, Immune Cell Infiltration and Changes of TRPC Channel Expression after Unilateral Ureteral Obstruction in Trpc6-/- Mice.Trpc6基因敲除小鼠单侧输尿管梗阻后肾纤维化、免疫细胞浸润及TRPC通道表达变化
Cell Physiol Biochem. 2019;52(6):1484-1502. doi: 10.33594/000000103.
10
In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease.体内选择性抑制 TRPC6 型离子通道可改善心脏和肾脏疾病中的纤维化和功能障碍。
Proc Natl Acad Sci U S A. 2019 May 14;116(20):10156-10161. doi: 10.1073/pnas.1815354116. Epub 2019 Apr 26.